HCC-UK 2020 Annual Conference
‘Questioning Current Practice’

Thursday 12th March 2020 – HCC-UK Research Focus

1300-1330  Registration

1330-1530  Scientific Focus 2020 – HUNTER Accelerator Award
Translating the immune environment of HCC into Clinical Practice
Chairs: Helen Reeves and Shish Shetty

1340-1405  The Immunosuppressive Niche in HCC – Professor Derek Mann, Professor of Hepatology, Newcastle University

1405-1430  Decoding HCC immunology by multi-omics – Professor Josep Llovet, Professor of Medicine-Hepatic Oncology, IDIBAPS-Hosp Clinic, University of Barcelona.

1430-1455  NMR spectroscopy with microfluidics – Liver slice applications – Professor Marcel Utz, Professor of Magnetic Resonance, University of Southampton

1455-1520  Tumor secretome as a Pandora’s box containing the "secrets" of tumor immunouppression - Professor Vincenzo Barnaba, Sapienza Universita Di Roma

1520-1530  Discussion time – strengthening the scientific Network Prof Derek Mann

1530-1600  Refreshments and posters

1600-1700  Basic Science Abstracts
Chairs Matt Hoare and Tom Bird

1600-1612  O1 - Development of a personalised human immunocompetent ex-vivo model for hepatocellular carcinoma - Dr Elena Palma

1612-1624  O2 - Unique molecular traits for NASH-related Hepatocellular Carcinoma – Roser Pinyol

1624-1636  O3 - c-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development - Dr Jack Leslie

1636-1648  O4 - Tracking neutrophils within the hepatocellular carcinoma microenvironment – development of relevant orthotopic and ex-vivo 3D liver-HCC culture models - Dr Daniel Geh

1648-1700  O5 - LINE1 retrotransposons activate TGFB signaling in hepatocellular carcinoma - Dr Ruchi Shukla

*Programme is subject to change
1700-1800  Multi-centre trials  
Chairs Tim Meyer and Helen Reeves

1700-1712  HUNTER HCC-UK Cohort— sites open, recruitment update – Dr Louise MacDougal, Consultant Hepatologist, Freeman Hospital  
https://research.ncl.ac.uk/hunter/

1712-1724  TACE-3 (DEB-TACE and Nivo) - Prof Dan Palmer, Liverpool  
https://www.isrctn.com/ISRCTN12053408?q=&filters=conditionCategory:Cancer,recruitmentCountry:Ireland&sort=&offset=1&totalResults=36&page=1&pageSize=10&searchType=basic-search

1724-1736  Cubic study (CXCR2+Durvalumab) – Professor Jeff Evans, Professor of Translational Cancer Research & Honorary Consultant in Medical Oncology, University of Glasgow  
A29827: CRUK/19/014 CUBIC: A Phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with Durvalumab, in patients with advanced Hepatocellular Carcinoma (HCC)

1736-1748  PRIMER-1 Trial – Professor Tim Meyer, Professor Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, Royal Free and UCL Cancer Institute  
PRIMER-1: Perioperative pembrolizumab and lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

1748-1800  DELIVER – The Early Detection of Hepatocellular Cancer Liver Cancer – Professor Ellie Barnes, Prof. of hepatology and experimental medicine, University of Oxford  
https://www.oxcode.ox.ac.uk/news/funding-success-for-liver-cancer-early-detection

Friday 13th March 2020 – HCC-UK Clinical focus

0830-0915  HCC-UK Committee Meeting

0915-0945  Registration

0950-1000  Welcome – Dr Aileen Marshall, Royal Free Hospital London, Chair HCC-UK Committee

1000-1115  Changing practices for early and intermediate HCC  
Chairs: Vicky Snowdon and Teik Choon See

1000-1025  HCC Interactive Cases: HCV-HCC, when to use DAA - Doug Macdonald

1025-1050  HCC Interactive Cases: Who should have SIRT – Professor Derek Manas, Surgeon, Freeman Hospital  
O6 - Preliminary experience of Selective Internal Radiation Therapy (SIRT) for HCC at a UK centre – Dr John Reicher, Newcastle NHS Foundation Trust

*Programme is subject to change
1050-1115  HCC Interactive Cases: When to SABR - Dr James Good, Consultant Clinical Oncologist, Queen Elizabeth Hospital

1115-1145  Refreshments, networking and posters

1145-1235  Changing practices for early HCC
   Chairs: Abid Suddle and Anya Adair

1145-1210  Down-staging study report – Professor Doug Thorburn, Consultant Hepatologist, Royal Free Hospital

1210-1235  Change in national allocation - Dr Alex Gimson, Consultant Transplant Hepatologist, Cambridge University Hospitals

1235-1300  Clinical Abstracts
   Chairs: Abid Suddle and Anya Adair

1235-1247  O7 - The landscape of hepatocellular carcinoma in the UK in the past 20 years: the HCC-UK/NCRAS partnership - Anya Burton, NHS England

1248-1300  O8 - DNA-PK as a predictive biomarker in hepatocellular carcinoma - a focus on liquid biopsy tools - Misti McCain, Newcastle University

1300-1400  Lunch and poster reviewing

1400-1430  Questioning Current Practice - State of art lecture
   Chair: Aileen Marshall

   Surveillance for HCC – Time to Stratify Risk? – Professor Helen Reeves, Professor of Liver Cancer, Newcastle University

1430-14645  ONCOLOGY – Which Treatment and who for
   Chairs: Tim Meyer and Bristi Basu

1430-1450  Locoregional therapy – When to stop – Dr Abid Suddle, London

1450-1515  First line therapy – Professor Jeff Evans, Professor of Translational Cancer Research & Honorary Consultant in Medical Oncology, University of Glasgow

1515-1540  Coffee

1540-1550  O9 - Suitability for second-line systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma: a UK single-centre experience - Dr Omar Fakih, Christie, Manchester

*Programme is subject to change
1550-1610 Interactive CASE Evolving systemic therapy in HCC – Dr Bristi Basu, Academic Consultant in Medical Oncology, University of Cambridge

1610-1630 Sequential therapies and clinical trials – Dr Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust

1630-1645 Panel Discussion

1645-1700 Closing Remarks and Poster prize
Aileen Marshall

This event has been sponsored/supported by Bristol Myers Squibb Pharmaceuticals by purchasing exhibition stand space.

*Programme is subject to change